

Dostarlimab

RUBY

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit



#### Serious and disabling adverse effects



#### Other adjustments



### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: FDA: Dostarlimab with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adult patients with primary advanced or recurrent endometrial cancer (EC). EMA: Dostarlimab is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.

Experimental Arm: Dostarlimab + Carboplatin + paclitaxel

Control Arm: Placebo + carboplatin + paclitaxel

